Groundbreaking research on ruxolitinib and decitabine combination therapy for accelerated and blast-phase myeloproliferative neoplasms (MPN-AP/BP).
Discover how U1 spliceosomal RNA mutations drive chronic lymphocytic leukemia and represent a novel non-coding hotspot driver mutation with clinical significance.
Discover how gene expression patterns in blood may predict treatment success for chronic myeloid leukemia patients, enabling personalized therapy approaches.
Exploring how epigenetic silencing of HOXA genes through DNA hypermethylation drives leukemia progression and treatment resistance.